Scientist thinking about immunotherapy research questions

What if I had an up-to-date overview of CAR T cell design and engineering?

 

Chimeric Antigen Receptor T Cells are ‘living drugs’ designed to eliminate cancer cells. In 2017, the first cancer treatment using CAR T Cells was approved by the FDA. Lonza has sponsored a poster, published by Nature Reviews Drug Discovery, which summarizes the latest developments in CAR T cell engineering.

 

Free Poster:

 

Order Your Print Copy

 

Download the free poster as a high-resolution PDF.



Solving Today's Challenges in Immunotherapy 

Lonza can provide high quality primary cells, transfection technology and services to support your transition from research into therapy.


Learn more about other immunotherapy products and resources:

 Hematopoietic and Immune Cells  Transfection of Immune Cells  Immunotherapy Knowledge Center

 

 

 

 

 

 

 

Technical Resources


Collection of white papers thumbnail 

 

Register to download PDFs >

White Papers and Technical Guides

 

Register and download these White Papers and Technical Guides on immunotherapy:

 

  • CRISPR/Cas9: using Nucleofection for efficient delivery of ribonucleoprotein (RNP) for targeted gene editing
  • Th17 Differentiation of peripheral blood CD4+ T cells into functional Th17 cells using a bead-based activation technology.
  • Genome Editing using Nucleofector™ Technology

 


CAR T Cells in Cancer Therapy wall chart - thumbnail
 


Download PDF >


Request Print Copy >

Free poster: CAR T cells in cancer therapy 
published by Nature Reviews Drug Discovery


T cells engineered to express chimeric antigen receptors (CARs) are 'living drugs' designed to eliminate cancer cells. Lonza has sponsored a poster, published by Nature Reviews Drug Discovery, which shows an overview of the different ways to design and generate CAR T cells and the journey to FDA approval in 2017.


Download the free poster as a high-resolution PDF, and request your own print copy to display in your lab.

 


GEN webinar Validating and Scaling CRISPR Applications - thumbnail
 

 

View Recording >

Webinar: Validating and Scaling CRISPR Applications 
presented by GEN


The therapeutic potential of the genome editing system CRISPR-Cas9 has ignited the imaginations of basic science and clinical researchers. As this cutting-edge science rapidly advances, it is important for researchers to have a firm grasp on appropriate target validation techniques and scalable methodologies that will allow CRISPR technology to progress efficiently. These topics and more are addressed in this 60-minute free webinar recording.

 


Nature Biotechnology webcast on CAR-T cells: Latest advances and outstanding challenges - thumbnail
 

 

View Recording >

Nature Biotechnology Webcast on CAR-T Cells: Latest Advances and Outstanding Challenges 
presented by Nature Biotechnology


The efficacy of CAR-T cells in acute lymphoblastic leukemia has ignited the field, as researchers and clinicians move to advance the technology. Watch this 60-minute free webinar recording and learn about the latest advances and outstanding challenges in the fast paced research environment of CARs with experts that bridge the lab and clinic.

 


Nature NK Cells Poster thumbnail 


Download PDF >


Request Print Copy >

Free poster: Therapeutic approaches to enhance natural killer cell cytotoxicity 
published by Nature Reviews Drug Discovery


Natural killer (NK) cells are emerging as attractive candidates for new immunotherapeutic approaches – they have the potential to induce powerful antigen-independent immune responses against malignancies. Lonza has sponsored a poster, published by Nature Reviews Drug Discovery, which discusses NK cells in immunotherapy.


Download the free poster as a high-resolution PDF, and request your own print copy to display in your lab.

 


Nature Immunotherapy Webinar thumbnail 

 

View Recording >

Webinar: Cancer Immunotherapy 
presented by Nature


Immunotherapy has the potential to achieve long-lasting regression and prevent relapse in cancer patients. View a recording of the Nature webinar, sponsored by Lonza to hear panel experts describe some of the most promising approaches to cancer immunotherapy, and the challenges that remain in translating scientific advances to clinical use.